1·Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
2·Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.
尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。
3·NIHSS scores were determined before tissue plasminogen activator bolus and at 60 and 120 minutes in both data sets.
在两个试验中，在组织纤维蛋白溶酶原激活剂使用前，都先用NIHSS评分。
4·Plasminogen activator inhibitor-1 (PAI-1) is a single strand glycoprotein, which can inhibit plasminogen activation.
纤溶酶原激活物抑制剂1 (PAI - 1)是一种单链糖蛋白，起抑制纤溶活性的作用。
5·Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
6·Objective to observe the effect of recombinant tissue plasminogen activator in the treatment of acute myocardial infarction.
目的观察应用重组组织型纤溶酶原激活剂溶栓治疗急性心肌梗死的效果。
7·Objective: To identify the significance of urokinase-type plasminogen activator expression in patients with epithelial ovarian carcinoma.
目的：探讨尿激酶型纤溶酶原激活因子的蛋白表达与上皮性卵巢癌生物学行为的关系。
8·Objective To study the changes of the endothelial tissue plasminogen activator reserve capacity in patients with acute coronary syndromes.
目的探讨急性冠状动脉综合征患者内皮组织纤溶酶原激活剂储备功能的变化规律。
9·Objective To investigate the relationship between the plasminogen activator inhibitor 1(PAI 1) promotor region gene polymorphism and cerebral stroke.
目的探讨纤溶酶原激活物抑制物- 1（ PAI- 1）启动子区基因多态性与脑卒中的关系。
10·Objective to study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).
目的研究纤溶酶原激活物抑制剂(PAI1)与肝细胞癌(HCC)生物学特性的关系。